Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitors in Idiopathic Inflammatory Myopathies
NCT05400889Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution, baricitinib in idiopathic inflammatory myopathies (IIM), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
tofacitinib oral solutionbaricitinib
03
Conditions
idiopathic inflammatory myopathies (IIM)
Beyond the preview
Go deeper on NCT05400889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400889.